Step-up treatment

Starting with milder medicines and moving on to stronger ones only if the milder ones do not work.

Also called: step up, accelerated step-up, conventional step-up, step-up, stepup, escalation

Related words top-down treatment treat to target

Topics Medicines Research

Questions people ask

What is the difference between 'step-up' and 'top-down' treatment?

Step-up means starting with simpler treatments such as steroids and only moving on to stronger medicines if those do not work. Top-down means starting a biologic early, usually infliximab together with an immunomodulator. The UK PROFILE trial found that, in newly diagnosed people with active Crohn's, top-down treatment led to far more steroid-free and surgery-free remission after a year, and fewer hospital stays and complications after five years. The 2025 BSG guideline now suggests early infliximab for moderate to severe Crohn's.

Sources

What is 'top-down' treatment and is it better?

Top-down means starting strong treatment, such as a biologic plus an immunosuppressant, soon after diagnosis instead of trying milder medicines first ('step-up'). In the UK PROFILE trial of newly diagnosed adults, 79% on top-down treatment stayed in remission without steroids or surgery for a year, compared with 15% on step-up, with fewer flares and operations. Your team will weigh this up for your own situation.

Source

What does 'treat to target' mean?

It means your team agrees goals in advance and adjusts treatment until you reach them, rather than waiting for symptoms. The STRIDE-II expert agreement says early goals are feeling better and getting blood and poo inflammation tests back to normal; longer-term goals are a healed bowel lining, no disability, good quality of life and normal growth in children. The CALM trial found that stepping up treatment when tests showed inflammation, not just when symptoms flared, led to more bowel healing.

Sources

Can Crohn's come back after surgery, and how is that prevented?

Yes. Crohn's & Colitis UK says Crohn's may return after surgery; doctors often check the area around the bowel join with a colonoscopy. NICE suggests azathioprine, often with up to three months of metronidazole, after a complete ileocolonic resection. The POCER trial and a Cochrane review support checking with a colonoscopy after surgery and stepping up treatment if needed. The 2025 BSG guideline suggests offering early advanced treatment, especially to people at higher risk, such as smokers.

Sources

Where to read more

A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE)

The Lancet Gastroenterology & Hepatology Study May 2024 Patients and professionals

A large UK-led trial of 386 newly diagnosed adults. Starting straight away with infliximab plus an immunosuppressant ('top-down') kept 79% in remission without steroids or surgery for a year, compared with 15% using the usual 'step-up' approach of trying milder drugs first. There were also fewer flares, serious side effects and operations. A blood test meant to predict who needed strong treatment did not help. Free to read in full.

Topics Biologics and newer medicines Research About Crohn's disease

Jargon explained top-down treatment step-up treatment biomarker steroid-free remission top-down step-up immunomodulator randomised controlled trial

Guideline review: 2025 British Society of Gastroenterology guidelines on inflammatory bowel disease in adults - Part 1: Crohn's disease

Frontline Gastroenterology (via PMC) Guide Nov 2025 For professionals

A readable summary of what the 2025 BSG guideline says about Crohn's. Key points: early 'top-down' infliximab with an immunomodulator for moderate to severe disease; avoiding long or repeated steroid courses; no longer suggesting immunomodulators alone; upadacitinib and risankizumab added; vedolizumab no longer routinely suggested; drug-level testing for anti-TNFs; early surgery as an option for limited ileocaecal disease; and offering early treatment after resection.

Topics Medicines Surgery Monitoring

Jargon explained top-down step-up therapeutic drug monitoring ileocaecal resection Rutgeerts score immunogenicity

Long-term outcomes of top-down therapy versus a conventional step-up strategy in adults newly diagnosed with Crohn's disease: 5-year follow-up of the PROFILE trial

The Lancet Gastroenterology & Hepatology Study Nov 2026 For professionals

Five-year follow-up of the PROFILE trial. People who had early top-down treatment were less likely to be admitted to hospital or to develop strictures or fistulas than those treated step-up, with no difference seen in serious infections or cancers, suggesting early treatment may change the course of the disease.

Topics Biologics and newer medicines Research

Jargon explained top-down step-up disease modification stricturing penetrating disease

Crohn's disease management after intestinal resection: a randomised trial (POCER)

The Lancet Study Feb 2015 For professionals

A trial of how to stop Crohn's returning after bowel surgery. Treating people according to their risk, checking with a colonoscopy at six months and stepping up treatment if the disease had come back worked better than standard drug treatment alone. It also showed that even low-risk patients need monitoring.

Topics Surgery Monitoring Research

Jargon explained post-operative recurrence colonoscopy step-up resection

Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial

The Lancet Study Dec 2017 Patients and professionals

CALM compared deciding treatment on symptoms alone with 'tight control', where treatment was stepped up if blood or poo tests (CRP and faecal calprotectin) showed inflammation even when people felt fine. After 48 weeks, 46% in the tight control group had a healed bowel lining compared with 30% in the symptom-only group. It is a cornerstone of the 'treat to target' approach.

Topics Monitoring Biologics and newer medicines Research

Jargon explained tight control faecal calprotectin CRP mucosal healing treat to target

Colonoscopy-guided therapy for the prevention of post-operative recurrence of Crohn's disease

Cochrane (via PMC) Systematic review Aug 2020 Patients and professionals

A Cochrane review suggesting that stepping up treatment based on a colonoscopy after surgery may reduce Crohn's coming back compared with waiting for symptoms. Whether to start treatment immediately after surgery or only after a colonoscopy remains uncertain.

Topics Surgery Monitoring Research

Jargon explained post-operative recurrence colonoscopy prophylaxis

STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD)

Gastroenterology Guideline Apr 2021 For professionals

An international expert agreement on what 'treat to target' should aim for in IBD. Short-term goals are feeling better and getting blood and poo inflammation tests back to normal. Long-term goals include a healed bowel lining seen at endoscopy, no disability, a normal quality of life, and normal growth in children. Healing through the full bowel wall in Crohn's is not yet a formal target but is a sign of deeper remission.

Topics Monitoring Research Medicines

Jargon explained treat to target endoscopic healing transmural healing biomarker calprotectin CRP clinical remission

Piles (haemorrhoids)

NHS Web page Apr 2026 For patients

Explains piles: lumps in and around the anus that commonly cause bright red blood after a poo, itching, mucus on the paper and a feeling of not having finished. Lists self-care steps, what a pharmacist can offer and hospital treatments such as banding. Says to get an urgent GP appointment or use 111 if you have piles with painless bleeding, a high temperature or pus leaking.

Topics Bleeding from the bottom Around the bottom (perianal) Symptoms

Jargon explained haemorrhoids rubber band ligation sclerotherapy laxatives

ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment

European Crohn's and Colitis Organisation (J Crohns Colitis) Guideline Oct 2024 For professionals

Europe's main expert guideline on which medicines to use for Crohn's disease, published as the first of a two-part set (the second covers surgery). It weighs up the trial evidence for steroids, immunosuppressants, biologics and newer tablets, including treatment of disease around the back passage. UK specialists use it alongside the BSG guideline.

Topics Medicines Biologics and newer medicines Immunosuppressants Around the bottom (perianal)

Jargon explained biologic immunomodulator induction maintenance de-escalation perianal fistula GRADE

Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review

Journal of Crohn's and Colitis via PubMed Central Systematic review Feb 2020 For professionals

Reviews the evidence for 'treat to target', where treatment is adjusted not just to symptoms but to measured goals such as a healed bowel lining and normal blood or poo markers. It explains the idea behind the STRIDE targets and notes that firm proof that aiming for healing improves long-term outcomes was still emerging.

Topics Monitoring Research

Jargon explained treat to target mucosal healing biomarker STRIDE

Biologic medicines and other targeted treatments

Crohn's & Colitis UK Guide Jul 2023 For patients

An overview of biologics and other targeted medicines for Crohn's and Colitis, with a table of each medicine, its brand names and how it works. It explains that biologics are lab-made antibodies given by drip or injection, and covers biosimilars, anti-TNFs, interleukin inhibitors and JAK inhibitors.

Topics Biologics and newer medicines Medicines

Jargon explained biologic biosimilar anti-TNF IL-23 inhibitor JAK inhibitor advanced therapy

Search everything for "step-up treatment"